The Novo Nordisk Foundation (NNF) is awarding a new 5-year grant of DKK 156 million to Danish Diabetes Academy (DDA), to support education of the next generation of diabetes researchers, as well as networking and research collaboration initiatives. The overall goal is to ensure that diabetes research in Denmark remains at the highest international level.
OPTIMAL OPPORTUNITIES FOR YOUNG RESEARCHERS TO IMPROVE AND PURSUE A CAREER WITHIN DIABETES RESEARCH
DDA is a nationwide initiative for research on diabetes and for research training, convening junior and senior researchers from universities, hospitals and the life-science industry in Denmark. DDA’s overall goal is to improve the quality of research training within diabetes. One specific goal is to provide young researchers with optimal opportunities to improve and pursue a career within the field.
NEW FUNDING OPPORTUNITIES, AND MORE EDUCATIONAL AND NETWORKING ACTIVITIES TO COME
DDA plans to use the NNF’s new grant to launch many initiatives, including organizing educational activities, such as PhD and postdoctoral courses, specifically focusing on developing talent and career opportunities among young diabetes researchers. In addition, DDA will offer up to 45 PhD scholarships and 40 postdoctoral fellowships, and several international visiting professorships. DDA will organize several outreach events to strengthen networks and establish collaboration between researchers in Denmark and internationally.
PROFESSOR ALLAN FLYVBJERG IS APPOINTED CHAIR OF THE NEW BOARD OF DIRECTORS
DDA is a Danish initiative led strategically by a diverse Board. A secretariat manages DDA, which is located at Odense University Hospital.
Allan Flyvbjerg, Professor, CEO of Steno Diabetes Center Copenhagen, Capital Region of Denmark, has been appointed Chair of the Board of Directors.
“The ambition of Danish Diabetes Academy is to train the future generation of diabetes researchers to adopt intersectoral and interdisciplinary approaches to their work. The overall purpose is to enable researchers to develop new types of treatment that can prevent the negative individual and societal effects of diabetes,” says Allan Flyvbjerg.
ODENSE UNIVERSITY HOSPITAL WILL CONTINUE TO HOST DDA
Niels Nørgaard Pedersen, CEO, Odense University Hospital, says:
“We are very pleased to receive the grant, and very pleased that Odense University Hospital will be able to continue hosting the secretariat of Danish Diabetes Academy. In the past 5 years, DDA has established itself as a key actor in training young talented diabetes researchers and as a national networking platform for the entire diabetes research community in Denmark. The Novo Nordisk Foundation’s continuing support for DDA will benefit the training and education of young Danish diabetes researchers and will thereby be decisive in maintaining Danish diabetes research in Denmark at its high international level.”
The core of DDA is the secretariat, located at Odense University Hospital, but the participating researchers are employed at various universities and hospitals throughout Denmark. The secretariat will create a platform for collaboration and develop new activities.
Source: Newsroom, Novo Nordisk Fonden